Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/13543780802528625
Reference22 articles.
1. Current Options in the Prevention of Thromboembolic Disease
2. Coagulation Factor Xa Inhibition: Biological Background and Rationale
3. Factor Xa or thrombin: is factor Xa a better target?
4. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis
Cited by 62 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Apixaban Pharmacokinetics and Bioequivalence of Two Tablet Formulations: A Randomized, Open‐Label, Crossover Study, Fasting Condition in Healthy Indonesian Volunteers;Clinical Pharmacology in Drug Development;2024-04-30
2. Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area;Pharmaceutics;2021-02-11
3. Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review;Analytica Chimica Acta;2019-10
4. In vitro Bioaccessibility, Bioavailability, and Plasma Protein Interaction of New Oral Anticoagulants in the Presence of Macronutrients;Current Pharmaceutical Biotechnology;2019-01-08
5. A study on indices of apixaban anticoagulation: A single-center prospective study;Journal of Pharmacological Sciences;2018-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3